At the vanguard of Mitochondrial research
Employees: 1-10
Total raised: $51.3M
Investors 1
| Date | Name | Website |
| 04.01.2022 | ND CAPITAL | nd.capital |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 21.08.2024 | Series A | $30.7M | - |
| 15.12.2023 | Series A | $20.6M | ND CAPITAL |
Mentions in press and media 19
| Date | Title | Description |
| 18.08.2026 | Three Swiss biotechs report progress across their clinical programmes | MoonLake Immunotherapeutics, a Zug-based clinical-stage biotech founded in 2021, reported topline results from IZAR-1, a Phase 3 trial of its lead candidate sonelokimab in adults with active psoriatic arthritis who have not previously rece... |
| 19.06.2026 | Swiss biotechs display their innovations at BIO 2026 in San Diego | The BIO International Convention attracts over 1,600 exhibitors and 21,000 attendees who network intensively over 4 days, discover new opportunities and promising partnerships. The attendees benefit from a broad spectrum of life sciences a... |
| 03.12.2025 | Four biotech startups reach key milestones | MUVON Therapeutics AG, which is focused on the treatment of stress urinary incontinence (SUI) in women, has achieved positive topline results from the Phase 2 clinical trial SUISSE-MPC2 (NCT05534269) evaluating its novel proprietary muscle... |
| 27.12.2024 | Vandria’s first clinical trial launched | Vandria is focussed on mitochondrial therapeutics developing first-in-class small molecule mitophagy inducers. VNA-318 is an orally available first-in-class small molecule against a novel target to rejuvenate cells and treat age-related di... |
| 08.11.2024 | Bio-Europe: Switzerland's Biotech Showcase in Stockholm | The heart of Europe beats strong in Stockholm this November. Bio-Europe, the continent's premier partnering event for the life sciences, is back for its 30th edition. This year, it promises to be a melting pot of innovation, collaboration, ... |
| 05.11.2024 | Bio Europe in Stockholm hosts 33 Swiss companies | Currently in its 30-year-edition, BIO-Europe remains Europe's leading partnering event, for the life sciences ecosystem, providing an exceptional opportunity to explore the latest trends learn and connect with potential partners. The past ... |
| 22.08.2024 | The Future of Health and Agriculture: Innovations in Mitochondrial Therapeutics and Soil Carbon Sequestration | In a world grappling with aging populations and climate change, two startups are carving paths toward solutions. Vandria and CinSOIL are not just companies; they are harbingers of hope. Each is tackling monumental challenges: one in health,... |
| 21.08.2024 | Vandria raises $30.7M Series A for mitochondrial therapeutics development | Mitochondrial therapeutics company Vandria today announced the second closing of its Series A financing bringing the final amount raised to date to $30.7 million (CHF 28.3 million). Vandria is developing first-in-class small molecule mitoph... |
| 21.08.2024 | Vandria Raises Second Series A; Round Totals $30.7M | Vandria, a Lausanne, Switzerland-based mitochondrial therapeutics company, raised an undisclosed amount in its second Series A funding. The round, which brought the total amount to $30.7M, saw participation from Hevolution Foundation and Do... |
| 21.08.2024 | Over CHF 14M secured to support Vandria's momentum | Vaud based biotech Vandria is developing first-in-class small molecule mitophagy inducers against a novel target to rejuvenate cells and treat age-related and chronic diseases in the fields of Muscle- and CNS diseases with large unmet medic... |
Show more